Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-22

Clinical Trial Update: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 [Phase 3]

View source ↗

Summary

Phase 3 trial update showing goal achievement after using an anti-PCSK9 antibody in statin-intolerant individuals with hyperlipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • anti-PCSK9 antibody

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2015-12-22